Proton beam radiotherapy (PBT) was noninferior to radiofrequency ablation (RFA) for local progression-free survival (LPFS) in patients with recurrent hepatocellular carcinoma (rHCC), in addition to showing a tolerable safety profile, according to the APROH trial presented during the 2020 digital ILC.
The combination therapy sofosbuvir-seraprevir appears to be effective and well tolerated in patients with chronic hepatitis C virus (HCV) genotype 1 infection without cirrhosis, results of a phase III trial have shown.
Irinotecan monotherapy may be as effective as an irinotecan-containing doublet therapy for second-line chemotherapy (CT) for individuals with advanced gallbladder cancers (GBCs) who are progressing on first-line CT, the phase II GB SELECT trial has shown.
The Foundation for Innovative New Diagnostics (FIND) in partnership with the World Hepatitis Alliance (WHA) and the Drugs for Neglected Diseases initiative (DNDi) organized a webinar on 30 July 2020, in conjunction with World Hepatitis Day which showcased preliminary outcomes from the Unitaid-supported Hepatitis C Elimination through Access to Diagnostics (HEAD-Start) project. The Ministry of Health (MOH) representatives from each project country, including Malaysia, presented project outcomes from their respective country.
Liver dysfunction may also be a manifestation of the coronavirus disease 2019 (COVID-19), according to a new study. In patients with chronic hepatitis B virus (HBV) infection, COVID-19 may also trigger reactivation of the virus.
Antisense inhibition of DGAT2* – one of two vital enzymes in triglyceride synthesis – may be a favourable strategy for reversing nonalcoholic fatty liver disease (NAFLD), suggesting that targeting this pathway may mitigate NAFLD progression to its more severe form, nonalcoholic steatohepatitis (NASH), a phase II study has shown.
In view of the prevalence and prognostic significance of liver derangement in patients with coronavirus disease 2019 (COVID-19), the Asia-Pacific Working Group for Liver Derangement during the COVID-19 Pandemic has issued practical recommendations on 12 clinical scenarios commonly encountered by physicians.
Patients with acute intermittent porphyria (AIP) – the most common subtype of acute hepatic porphyria (AHP) – had significantly reduced attack rates, as well as improvements in other parameters, with givosiran, the phase III ENVISION trial has shown.
Adding dapagliflozin (DAPA) and saxaglipitin (SAXA) to routine metformin treatment in type 2 diabetes (T2D) leads to a decrease in liver fat and adipose tissue, according to a new study presented at The Liver Meeting Digital Experience by the American Association for the Study of Liver Diseases (AASLD 2020).
The small molecule fatty acid synthase inhibitor TVB-2640 boasts a win in addressing the three key drivers of nonalcoholic steatohepatitis (NASH)—namely liver fat, fibrosis, and inflammation—in the phase II FASCINATE-1 trial presented during The Liver Meeting Digital Experience of the American Association for the Study of Liver Diseases (AASLD).